Biocon Limited (NSE:BIOCON)
India
· Delayed Price · Currency is INR | Market Cap | 424.21B |
| Revenue (ttm) | 152.62B |
| Net Income (ttm) | 10.13B |
| Shares Out | 1.20B |
| EPS (ttm) | 8.46 |
| PE Ratio | 41.90 |
| Forward PE | 52.36 |
| Dividend | 0.50 (0.15%) |
| Ex-Dividend Date | Jul 4, 2025 |
| Volume | 1,057,802 |
| Average Volume | 2,517,958 |
| Open | 355.00 |
| Previous Close | 354.45 |
| Day's Range | 352.80 - 357.55 |
| 52-Week Range | 291.00 - 404.70 |
| Beta | 0.22 |
| RSI | 65.48 |
| Earnings Date | Jul 30, 2025 |
About Biocon
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psor... [Read more]
Financial Performance
In 2024, Biocon's revenue was 152.62 billion, an increase of 3.43% compared to the previous year's 147.56 billion. Earnings were 10.13 billion, a decrease of -0.90%.
Financial StatementsNews
Biocon launches BioWISE program to empower women in STEM across Karnataka
Biocon Foundation, the CSR arm of Biocon Group, has announced the launch of its new BioWISE (Women in STEM Empowered) program in partnership with the National Centre for Biological Sciences (NCBS) and...
Top stocks to watch today, June 3: HCLTech, Mphasis, Britannia Industries, Torrent Power, Biocon and more
As Dalal Street opens for trade on Tuesday, June 3, market participants will focus on specific stocks driven by recent announcements, corporate developments, and macroeconomic cues. The previous sessi...
Stocks to watch on June 3: Biocon, PTC India Financial, HCL Tech, Yes Bank, Maruti, Reliance Infra, Aptus Value, Zinka Logistics, Adani Group in focus
Indian equities are set to open with a host of stock-specific triggers on June 3, with several companies announcing business developments, regulatory updates, and block deals. Positive developments Bi...
Biocon receives CDSCO approval for its Liraglutide drug in India
Biocon Limited, a global biopharmaceutical company, has announced that it has received regulatory approval in India for its Liraglutide drug substance. Its wholly owned subsidiary, Biocon Pharma Limit...
‘Metro Mentor’ moment: Kiran Mazumdar-Shaw ditches car, hops on Bengaluru Metro with Exxon Mobil’s ‘Iron Lady’; calls ride ‘quick way to avoid traffic’
Biocon founder Kiran Mazumdar-Shaw opted for the Namma Metro's Purple Line to bypass Bengaluru's notorious traffic, traveling from Whitefield to Vidhana Soudha. She lauded the Bangalore Metro Rail Cor...
Biocon Biologics receives UK MHRA approval for YESINTEK, Biosimilar Ustekinumab
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd., has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for YESINTEK®, a bio...
Biocon subsidiary and Yoshindo expand access to Ustekinumab Biosimilar in Japan
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, announced that its commercial partner in Japan, Yoshindo Inc., has launched Ustekinumab BS Sub...
Stocks to watch on May 16: Websol, Godrej Industries, Crompton, Biocon, RVNL, Lupin, BLS in focus after Q4 earnings and updates
Several companies are in focus following their quarterly earnings announcements and corporate disclosures. From sharp turnarounds in profits to regulatory approvals and strategic expansions, here’s a ...
JP Morgan, Goldman Sachs & more: Top stocks on brokers' radar for today
Brokerage firms have varying outlooks on Indian companies. JP Morgan is underweight on Dr. Reddy's due to margin concerns, while Citigroup maintains a buy rating on Biocon despite weak numbers. Nomura...
Biocon share price falls today – Should you buy, hold or sell? Check what brokerages say
Shares of Biocon Ltd declined 0.33% to ₹328.80 on Monday despite bullish brokerage commentary and upside estimates of up to 30%. The stock, which closed at ₹329.90 in the previous session, saw muted i...
Stocks to watch on May 9: Titan, BPCL, L&T, Biocon, MCX among key movers in trade today
Equity markets will be tracking a range of corporate announcements and quarterly earnings today. Several major companies across sectors have reported their March quarter results, while others have ann...
Biocon Q4FY25 results: Net profit jumps 153% YoY to Rs 344 crore; revenue rises 12% to Rs 4,454 crore
Biocon Limited reported a strong financial performance for the quarter and financial year ended March 31, 2025. For Q4FY25, consolidated revenue came in at Rs 4,454 crore, marking a 12% year-on-year (...
Stocks in focus: Asian Paints, Titan, LT, Britannia, Biocon among key firms to announce Q4 results today
On May 8, 2025, several prominent Indian companies are scheduled to release their financial results for the fourth quarter of fiscal year 2025. The list includes a diverse set of firms across various ...
Biocon share price jumps 4% after its subsidiary receives multiple market access agreements for Yesintek
Biocon shares jumped 4% in early trade after the company announced that its subsidiary, Biologics, had significant U.S. market access agreements for its biosimilar Yesintek™ (ustekinumab-kfce). As of ...
Biocon Biologics secures US market access for Yesintek
Biocon Biologics Ltd. (BBL), a global biosimilars company and subsidiary of Biocon Ltd., has announced that its biosimilar Yesintek™ (ustekinumab-kfce), approved by the U.S. Food and Drug Administrati...
Biocon shares jump over 2% after EU panel’s positive nod for denosumab biosimilars
Shares of Biocon Ltd rose 2.07% to ₹318.30 in early trade on April 28, 2025, after its subsidiary received a major boost from European regulators. The Committee for Medicinal Products for Human Use (C...
Biocon to raise Rs 4,500 crore via QIP or other routes
Biocon Limited has announced that its board of directors has approved a proposal to raise up to ₹4,500 crore through a mix of instruments, including equity shares, convertible securities, non-converti...
Eris Lifesciences, Lupin and Biocon shares in focus as Novo Nordisk exits Rs 800 crore Human Mixtard brand, says report
Shares of Eris Lifesciences, Lupin, and Biocon were in focus on April 23 after pharmaceutical major Novo Nordisk announced the discontinuation of its Human Mixtard insulin brand in India — one of the ...
Biocon shares in focus ahead of April 23 board meeting to consider fundraise proposal
Shares of Biocon Limited are expected to be in focus in the upcoming trading sessions as the company has informed exchanges about an important board meeting scheduled for April 23, 2025, to consider a...
Biocon shares jump 3% as its subsidiary secures US market entry for Yesafili
Biocon Ltd. shares surged 3% after its subsidiary, Biocon Biologics Ltd., announced a major breakthrough in the U.S. market with the confirmed entry of Yesafili™ (aflibercept-jbvf)—an interchangeable ...
Biocon Biologics secures U.S. market entry for Yesafili™, an interchangeable biosimilar to Eylea®
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has announced a significant milestone in its U.S. expansion with the confirmation of a market entry date for Yesafili™ (aflibercept-jbvf), an interc...
Biocon shares rise over 3% as USFDA approves bevacizumab biosimilar Jobevne™ for cancer treatment
Shares of Biocon Ltd surged 3.07% to ₹315.70 in Friday’s early trade after its subsidiary, Biocon Biologics Ltd (BBL), secured approval from the U.S. Food and Drug Administration (USFDA) for its bevac...
Top stocks to watch today, April 11: Tata Steel, Infosys, TCS, BHEL, Aurobindo Pharma, Biocon and more
The Indian stock market could open on a negative note today (Friday, April 11), as indicated by Gift Nifty. At 8:27 AM, Gift Nifty was seen trading at 22,934, down 0.48%. The Indian stock market may o...
Biocon Biologics receives U.S. FDA approval for bevacizumab biosimilar JOBEVNE
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON), has received approval from the U.S. Food and Drug Administration (FDA) for its bevacizumab biosimilar, Jobevne™ (beva...
Biocon shares drop over 6% today; Board approves Rs 600 crore fundraise via commercial papers
Shares of biotechnology major Biocon Ltd slipped over 6% to ₹307.80 during Monday’s trade, following an announcement that the company’s board had approved raising up to ₹600 crore through the issuance...